

Argomenti

Bayesian applications in pharmaceutical studies

Real World Evidence in Health Care Research: How Can It Improve Scientific Knowledge?"

From a Niche to the Headlines: Spotlights on Statistics in Vaccines Development

A deep dive into the Digital Health Revolution

Costo del Forum

100€+IVA per soci SIMeF e studenti

200€+IVA per non soci SIMeF

L'iscrizione va finalizzata entro il 24 settembre 2021 presso la segreteria SIMeF al link:

[IBIG Forum 2021-Attività SIMeF - Società Italiana di Medicina Farmaceutica](#)

Col contributo educativo di



IBIG Forum 2021

4-5-6 ottobre 2021

9,00 – 13,30

Comitato Scientifico FORUM

Daniele Bottigliengo
Marco Costantini
Angela Gambioli
Luca Grassano
Arturo Lanzarotti
Andrea Nizzardo
Veronica Sciannameo
Giulia Zigon

Con il patrocinio di



POLITECNICO
DI TORINO

IBIG FORUM

4-6 OCTOBER 2021

AGENDA

DAY 1

Real World Evidence in Health Care Research: How Can It Improve Scientific Knowledge?

IBIG Moderators: Veronica Sciannameo, Daniele Bottigliengo

	<i>Title</i>	<i>Speaker</i>
9.30 – 9.45	Forum presentation and introduction	IBIG
9.45 – 10.15	Potentialities, opportunities and limitations of the RWE	Sara Cazzaniga, Scientific Partnership Director, IQVIA
10.15 – 10.45	Population-based genetic association studies and identification of actionable molecular targets: concepts and examples.	Cristian Pattaro, Senior Researcher Eurac Research Institute for Biomedicine, Bolzano
10.45 – 11.30	Pathway to excelling in real-world evidence generation	Gian Paolo Fadini, Associate Professor of Endocrinology and Metabolism, University of Padua
11.30 – 11.45	<i>Break</i>	
11.45 – 12.15	TBC	Lucia Simoni, Medineos, an IQVIA company
12.15 – 12.45	A multiple imputation procedure for record linkage and causal inference to estimate the effects of home-delivered meals	Roe Gutman, Brown University School of Public Health, Providence

DAY 2

Bayesian applications in pharmaceutical studies

IBIG Moderators: Andrea Nizzardo, Angela Gambioli

	<i>Title</i>	<i>Speaker</i>
9.00 – 9.15	Introduction	IBIG
9.15 – 9.45	On the choice of the sample size for evidence and consensus in clinical trials	Fulvio De Santis, Full Professor of Statistics, University of Rome “La Sapienza”
9.45 – 10.15	Bayesian Adaptive Designs in Early Phase Development	Pantelis Vlachos, VP, Customer Success, Cytel Inc.
10.15 – 10.45	Overview of Bayesian Variable Selection methods	Marco Colpo, Senior Biostatistician, Parexel
10.45 – 11.00	<i>Break</i>	

From a Niche to the Headlines: Spotlights on Statistics in Vaccines Development

IBIG Moderators: Giulia Zigon, Luca Grassano

11.00 – 12.00	On the Definition of Vaccine Efficacy and Its Estimation	Mauro Gasparini, Full Professor of Statistics, Politecnico of Turin
12.00 – 12.30	An Introduction to the Correlate of Protection	Andrea Callegaro, Lead Statistician, GSK
12.30 – 13.00	A Case Study of a Vaccine Administered to Prevent COPD Exacerbations: Issues and Difficulties of a Study Performed on Patients.	Luca Moraschini, Principal Statistician, GSK
13.00 – 13.30	Regulatory Perspectives in Vaccine Development	Elisa Marmugj, Global Regulatory Manager, GSK

DAY 3

A deep dive into the Digital Health Revolution		
IBIG Moderators: Marco Costantini, Arturo Lanzarotti		
	<i>Title</i>	<i>Speaker</i>
9.00 – 9.15	Introduction	IBIG
9.15 – 9.45	Technological Innovation at the Service of Research on Chronic and Fragile patients: the SWAN Study Innovative Design – Rationale and Methodology	Chiara Ascardi, Medical Advisor Ophthalmology, Novartis Farma Marta Bartzaghi, Data Analytics Lead, Novartis Farma
9.45 – 10.15	Technological Innovation at the Service of Research on Chronic and Fragile patients: the SWAN Study Innovative Design – Operational and Technical Development	Diana Stirati, Study Manager Massimo Granata, Innovative Solution Manager, Novartis Farma
10.15 – 10.45	Standardized Data from Biobanks and Devices to Support Clinical Research and Predictive Medicine: the HIBAD Project	Massimo Beccaria, President, Advice Pharma Group
10.45 – 11.30	Analysis of physical Activity Data Using Generalized Additive Models: Practical Applications to ALS and COPD Studies	Edoardo Lisi, Statistician, GSK
11.30– 11.45	<i>Break</i>	
11.45 – 12.15	The “Digital Pharmacovigilance”	Ilenia Bocchi, Pharmacovigilance Country Head Deputy, Bayer Lisa Stagi, Patient Safety & Quality Lead, Roche
12.15 – 12.45	Wrap-up and conclusions	IBIG